Novel CETP Inhibitor Shows Coronary Improvements in Phase 3 Study

The primary endpoint was significant reduction in major coronary events
The primary endpoint was significant reduction in major coronary events

Merck announced positive results from its REVEAL trial that assessed their investigational cholesteryl ester transfer protein (CETP) inhibitor, anacetrapib.

The REVEAL trial (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) lasted for a median of at least 4 years and included 30,000 patients at high risk for cardiovascular events. Trial participants received the LDL-cholesterol lowering regimen, atorvastatin, and were randomized to receive either concomitant anacetrapib or placebo.

The primary endpoint of significant reduction in major coronary events (including coronary death, myocardial infarction, and coronary revascularization) for anacetrapib compared to placebo, was met. Adverse events were similar to those previously reported, including the accumulation of anacetrapib in adipose tissue.  

Related Articles

The full results of the REVEAL trial will be announced at the European Society of Cardiology meeting on August 29. The Company will review the results with an external panel of experts before deciding on whether they will file a new drug application (NDA) to the Food and Drug Administration (FDA). 

For more information visit Merck.com.